Mucopolysaccharidosis Treatment Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032

Growth Factors of Mucopolysaccharidosis Treatment Market

The mucopolysaccharidosis treatment market size was valued at USD 1.98 billion in 2018, and the market is now projected tgrow from USD 7.96 billion by 2032, exhibiting a CAGR of 10.4% during the forecast period of 2019-2026.

Most enzyme replacement therapies, such as Elaprase, are costly and thus only accessible ta few patients, restricting mucopolysaccharidosis treatments in particularly developing countries. Current approaches tthe treatment dnot reach the brain, thus excluding the neurological manifestations of the condition. This condition fosters a demand for superior therapies taddress the unmet need. Anticipated launches of affordable alternatives are expected tboost the market. Improved treatment outcomes and better accessibility will propel the global mucopolysaccharidosis treatment market growth.

Rising research and development for rare diseases boosts the mucopolysaccharidosis treatment market share, driven by pipeline candidates from companies such as ArmaGen and REGENXBIO. Orphan diseases, including MPS, offer higher potential for blockbuster drugs than conventional treatments. Pharmaceutical firms focus on rare diseases due tfewer requirements for large outcome studies. This trend strengthens market growth and innovation in MPS therapies. Emerging markets for rare disease treatment and diagnosis will alsprobably drive market share-expanding investments in rare disease therapies during the forecast period.

Comprehensive Analysis of Mucopolysaccharidosis Treatment Market

The mucopolysaccharidosis treatment market and healthcare industry is rising at an exponential rate due tits market segmentation. This market expansion effectively provides a detailed regional assessments considering the dominant supply and demand forces that impact the healthcare industry. These segmentations are methodically segregated by treatment, by disease type, by route of administration and by end-user. The treatment includes, Enzyme Replacement Therapy (ERT) and Others. The disease type includes, Mucopolysaccharidosis Type I, Mucopolysaccharidosis Type II, Mucopolysaccharidosis Type IV A, Mucopolysaccharidosis Type VI and Others. The route of administration includes, Intravenous and Intracerebroventricular (ICV). The end-user includes, Hospitals, Specialty Clinics and Others.

The North American mucopolysaccharidosis treatment marketplace accounted for USD 1,019.4 million in 2018 and has a better market proportion. The contribution comes from great diagnosis/treatment rates and reimbursement policies. Superior diagnostic techniques and tools, improved patient consciousness, and comprehension and extended controlled trials and research work are some of the factors that drive the market. The industry players alsplay a key role in the development of the pipeline. Such aspects support that North America is the world’s most preferred destination for MPS treatment.

The top players in the market play a crucial role in the healthcare industry assuring industrial prospectus growth and setting market standards. These players include, Shire (Takeda Pharmaceutical Company Limited), Denali Therapeutics, ArmaGen, REGENXBIO Inc., SangamTherapeutics, BioMarin, Lysogene, Abeona Therapeutics Inc., Ultragenyx Pharmaceutical, Genzyme Corporation and Others. These market players provide a level-playing competitive landscape.

In February 2020, Lysogene, a main scientific biopharmaceutical organization, bagged the FDA fast-track label for the LYS-SAF302 gene therapy pipeline in MPS IIIA or Sanfilippsyndrome.

Segmentation Table

Global Mucopolysaccharidosis Treatment Market Scope

Study Period 2015-2026

Base Year 2018

Forecast Period 2019-2026

Growth Rate CAGR of 10.4% from 2019 t2026

Historical Period 2015-2017

Unit Value (USD billion)

Segmentation By Treatment, Disease Type, Route of Administration, End User, and Geography

By Treatment

• Enzyme Replacement Therapy (ERT)
• Others

By Disease Type

• Mucopolysaccharidosis Type I
• Mucopolysaccharidosis Type II
• Mucopolysaccharidosis Type IV A
• Mucopolysaccharidosis Type VI
• Others

By Route of Administration

• Intravenous
• Intracerebroventricular (ICV)

By End User

• Hospitals
• Specialty Clinics
• Others

By Geography

• North America (U.S. and Canada)
• Europe (U.K., Germany, France, Italy, Spain, and Rest of Europe)
• Asia-Pacific (Japan, China, India, South Korea, and Rest of Asia-Pacific)
• Rest of the World

Please Note: It will take 5-6 business days to complete the report upon order confirmation.